Reuters exclusively reported that a U.S. lawmaker involved in health policy has asked the Food and Drug Administration why it did not inspect Elon Musk’s Neuralink before allowing the brain implant company to test its device in humans.
Related stories
Exclusives | Americas
Read more
UBS hires Taylor Henricks as head of M&A in Americas from Morgan Stanley
1 July 2025
Exclusives | Americas
Read more
DOGE now targeting SEC policy, eyes SPAC rules, sources say
1 July 2025
Exclusives | Americas
Read more